AU2015278744B2 - Compositions and methods for visualization of the vitreous - Google Patents

Compositions and methods for visualization of the vitreous Download PDF

Info

Publication number
AU2015278744B2
AU2015278744B2 AU2015278744A AU2015278744A AU2015278744B2 AU 2015278744 B2 AU2015278744 B2 AU 2015278744B2 AU 2015278744 A AU2015278744 A AU 2015278744A AU 2015278744 A AU2015278744 A AU 2015278744A AU 2015278744 B2 AU2015278744 B2 AU 2015278744B2
Authority
AU
Australia
Prior art keywords
gly
tyr
lys
seq
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015278744A
Other languages
English (en)
Other versions
AU2015278744A1 (en
Inventor
Eric Carlson
Thaddeus Peter DRYJA
Joy GHOSH
Michael Roguska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AU2015278744A1 publication Critical patent/AU2015278744A1/en
Application granted granted Critical
Publication of AU2015278744B2 publication Critical patent/AU2015278744B2/en
Assigned to ALCON INC. reassignment ALCON INC. Request for Assignment Assignors: NOVARTIS AG
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
AU2015278744A 2014-06-25 2015-06-24 Compositions and methods for visualization of the vitreous Ceased AU2015278744B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462016731P 2014-06-25 2014-06-25
US62/016,731 2014-06-25
PCT/IB2015/054747 WO2015198245A1 (en) 2014-06-25 2015-06-24 Compositions and methods for visualization of the vitreous

Publications (2)

Publication Number Publication Date
AU2015278744A1 AU2015278744A1 (en) 2017-01-12
AU2015278744B2 true AU2015278744B2 (en) 2018-09-27

Family

ID=53539753

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015278744A Ceased AU2015278744B2 (en) 2014-06-25 2015-06-24 Compositions and methods for visualization of the vitreous

Country Status (8)

Country Link
US (1) US10537648B2 (https=)
EP (1) EP3160512B1 (https=)
JP (2) JP6296581B2 (https=)
CN (1) CN107206107A (https=)
AU (1) AU2015278744B2 (https=)
CA (1) CA2953682A1 (https=)
ES (1) ES2730398T3 (https=)
WO (1) WO2015198245A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242919A1 (en) * 2024-05-24 2025-11-27 Navigo Proteins Gmbh Novel binding proteins for hyaluronic acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063155A2 (en) * 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2014099997A1 (en) * 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733744A1 (en) 2005-06-17 2006-12-20 Ludwig-Maximilians-Universität München Method, dye and medicament for staining the internal limiting membrane and/or the capsule of an eye
JP4936508B2 (ja) * 2006-01-23 2012-05-23 独立行政法人国立国際医療研究センター 蛍光ナノ粒子を含む眼の硝子体染色剤及び染色方法
HUE026001T2 (en) * 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
US20110236310A1 (en) 2008-12-25 2011-09-29 Canon Kabushiki Kaisha Labeling composition for intraocular tissue, labeling method of intraocular tissue, and screening method
US8759298B2 (en) 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration
WO2012135432A2 (en) 2011-03-29 2012-10-04 Kemin Industries, Inc. Dyes for membranes and biological structures
EP3838293A1 (en) * 2012-07-11 2021-06-23 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
GB201400994D0 (en) * 2014-01-21 2014-03-05 Ucl Business Plc Drug delivery system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063155A2 (en) * 2011-10-24 2013-05-02 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2014099997A1 (en) * 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan

Also Published As

Publication number Publication date
US20170202981A1 (en) 2017-07-20
CA2953682A1 (en) 2015-12-30
US10537648B2 (en) 2020-01-21
WO2015198245A1 (en) 2015-12-30
JP2017524679A (ja) 2017-08-31
EP3160512A1 (en) 2017-05-03
ES2730398T3 (es) 2019-11-11
CN107206107A (zh) 2017-09-26
AU2015278744A1 (en) 2017-01-12
JP2018039847A (ja) 2018-03-15
JP6296581B2 (ja) 2018-03-20
EP3160512B1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
Farah et al. The use of vital dyes during vitreoretinal surgery-chromovitrectomy
Sreekumar et al. Intra-vitreal αB crystallin fused to elastin-like polypeptide provides neuroprotection in a mouse model of age-related macular degeneration
Fernández-Colino et al. Self-assembling elastin-like hydrogels for timolol delivery: development of an ophthalmic formulation against glaucoma
US12440443B2 (en) Nano-emulsion of CBFβ-RUNX1 inhibitor for ocular drug deliver
RU2561585C2 (ru) Местный глазной пептидный состав
TW201836646A (zh) 治療與血管生成及血管新生相關病症的方法
AU2020230409B2 (en) Method for the treatment of a disease using pigment epithelium-derived factor (PEDF)
Cai et al. Injectable self-assembling peptide hydrogel as a promising vitreous substitute
AU2015278744B2 (en) Compositions and methods for visualization of the vitreous
US12540171B2 (en) Compositions and methods for treating ocular disease
US11795200B2 (en) Nano small peptide and its use in preparation of drugs for treating and preventing fundus vascular diseases
CN109640973A (zh) 近视的治疗
Yamamoto et al. Visualizing vitreous using quantum dots as imaging agents
US11160881B2 (en) Dendrimer compositions for use in angiography
Talreja et al. G-quartet oligonucleotide mediated delivery of functional X-linked inhibitor of apoptosis protein into retinal cells following intravitreal injection
US20230087023A1 (en) Nano small peptide and its use in preparation of drugs for treating and preventing fundus vascular diseases
Junnuthula et al. Intravitreal polymeric nanocarriers with long ocular retention and targeted delivery to the retina and optic nerve head region. Pharmaceutics. 2021; 13 (4): 445
CN102083411B (zh) 载体
CN119192407B (zh) 一种多肽-地塞米松偶联物及其制备方法与应用
ES2991634T3 (es) Vasodilatadores para su uso en el tratamiento de un trastorno isquémico de la retina
Chaw Fundamental study of nanoliposomes for ocular therapy
Zaidi et al. A study of aqueous humour proteins in patients of primary open angle glaucoma
CN115869416A (zh) 用于眼部靶向递药的细胞膜、药物载体、组合物及其制备方法和用途
Farah et al. The during use vitreoretinal of vital dyes surgery–chromovitrectomy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALCON INC.

Free format text: FORMER OWNER(S): NOVARTIS AG

MK14 Patent ceased section 143(a) (annual fees not paid) or expired